Josepha Murray News Today

Learn more about services at Mayo Clinic.

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

Issuer: Immunic, Inc. / Key word(s): Conference Immunic to Participate in Scientific and Investor Conferences in July 29.06.2023 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to Participate in Scientific and Investor Conferences in July NEW YORK,...

– Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease Provide Proof-of-Concept for a New Therapeutic Approach to Treat Gastrointestinal...

Immunic, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update Positive Results From Phase 1b Clinical... | May 11, 2023

Issuer: Immunic, Inc. / Key word(s): Miscellaneous Immunic to Host Virtual Celiac Disease R&D Day to Highlight Current Pathways for Drug Development and Unmet Medical Need 09.02.2023 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to Host Virtu...

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...

Issuer: Immunic, Inc. / Key word(s): Conference Immunic to Participate in Scientific and Investor Conferences in February 25.01.2023 / 12:30 CET/CEST The issuer is solely responsible

Issuer: Immunic, Inc. / Key word(s): Conference Immunic to Participate in Scientific and Investor Conferences in February 25.01.2023 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to Participate in Scientific and Investor Conferences in February N...